Stockreport

Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

Seelos Therapeutics, Inc.  (SEEL) 
Last seelos therapeutics, inc. earnings: 5/21 05:12 pm Check Earnings Report
PDF NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapie [Read more]